Oncotelic Therapeutics (OTLC) Stock Price, News & Analysis

Company Overview

Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for cancer and other serious diseases. The company’s research has centered on RNA-based medicines and treatments designed to target biological pathways involved in tumor growth, immune regulation and disease progression.

Its lead product candidate, OT-101, is an antisense oligonucleotide designed to inhibit transforming growth factor beta 2 (TGF-β2), a signaling protein associated with tumor development and immune suppression. OT-101 has been evaluated in clinical studies involving cancers such as glioblastoma, pancreatic cancer and melanoma. The company has also pursued additional oncology and infectious-disease programs, although the status of individual programs may change as development progresses.

Oncotelic Therapeutics was formerly known as Mateon Therapeutics and adopted its current name as it expanded its focus on oncology and related therapeutic technologies. The company has been associated with Dr. Vuong Trieu, who has served in senior executive and leadership roles. Its activities have primarily involved research, clinical development and collaborations intended to advance its drug candidates in the United States and international markets.

Key Stats

• Today's Range: $0.02 to $0.02
• 50-Day Range: $0.02 to $0.05
• 52-Week Range: $0.02 to $0.11
• Volume: 480,132 shs
• Average Volume: 425,492 shs
• Market Capitalization: $9.50 million
• P/E Ratio: 0.04
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Oncotelic Therapeutics Stock Analysis - MarketRank™

Oncotelic Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Oncotelic Therapeutics.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oncotelic Therapeutics is 0.04, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oncotelic Therapeutics is 0.04, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.15.

Price to Book Value per Share Ratio

Oncotelic Therapeutics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Oncotelic Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Oncotelic Therapeutics has a short interest ratio ("days to cover") of 0.02, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Oncotelic Therapeutics has recently increased by 20.77%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oncotelic Therapeutics does not currently pay a dividend.

Dividend Growth

Oncotelic Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Oncotelic Therapeutics this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Oncotelic Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

39.22% of the stock of Oncotelic Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Oncotelic Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 4/15/2026
• Today: 10/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:OTLC
• CIK: 908259
• Web: www.mateon.com
• Phone: (650) 635-7000
• Fax: 650-635-7001
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.59
• Trailing P/E Ratio: 0.04
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $249.28 million
• Net Margins: N/A
• Pretax Margin: 143,532.39%
• Return on Equity: 123.75%
• Return on Assets: 81.36%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 0.08
• Quick Ratio: 0.08

Sales & Book Value

• Annual Sales: $70 thousand
• Price / Sales: 135.64
• Cash Flow: $0.52 per share
• Price / Cash Flow: 0.04
• Book Value: $0.59 per share
• Price / Book: 0.04

Miscellaneous

• Outstanding Shares: 456,493,000
• Free Float: 277,456,000
• Market Cap: $9.50 million
• Optionable: Not Optionable
• Beta: -0.18